Reports for APOTEX INC
Company Name
APOTEX INC
Totals |
||
Shortage reports |
3356 |
|
| Actual shortage: | 218 (6%) | |
| Anticipated shortage: | 0 (0%) | |
| Avoided shortage: | 10 (0%) | |
| Resolved: | 3128 (93%) | |
Discontinuation Reports |
359 |
|
| To be discontinued: | 24 (7%) | |
| Discontinued: | 335 (93%) | |
| Reversed: | 0 (0%) | |
Late reports |
144 (4%) |
|
Overdue reports |
62 (26%) |
|
Shortage reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-REPAGLINIDE | 2.0MG | TABLET | Resolved | 2017-03-11 | 2018-09-11 | 481 |
| APO-RILUZOLE | 50MG | TABLET | Resolved | 2019-07-12 | 2019-09-16 | 89170 |
| APO-RILUZOLE | 50MG | TABLET | Resolved | 2017-08-30 | 2018-02-28 | 20648 |
| APO-RILUZOLE | 50MG | TABLET | Resolved | 2020-01-15 | 2022-09-23 | 103385 |
| APO-RILUZOLE | 50MG | TABLET | Actual shortage | 2024-06-07 | 2024-12-19 | 229974 |
| APO-RISEDRONATE | 150MG | TABLET | Resolved | 2017-08-31 | 2017-10-20 | 20704 |
| APO-RISEDRONATE | 150MG | TABLET | Resolved | 2019-01-15 | 2019-03-11 | 72360 |
| APO-RISEDRONATE | 150MG | TABLET | Resolved | 2017-03-11 | 2017-03-15 | 484 |
| APO-RISEDRONATE | 35MG | TABLET | Resolved | 2017-03-11 | 2017-05-02 | 598 |
| APO-RISEDRONATE | 150MG | TABLET | Resolved | 2021-09-10 | 2022-03-04 | 145468 |
| APO-RISEDRONATE | 150MG | TABLET | Resolved | 2022-02-04 | 2022-03-07 | 154197 |
| APO-RISEDRONATE | 150MG | TABLET | Resolved | 2018-05-02 | 2018-07-03 | 47969 |
| APO-RISEDRONATE | 35MG | TABLET | Resolved | 2018-08-21 | 2018-10-19 | 58626 |
| APO-RISEDRONATE | 35MG | TABLET | Resolved | 2018-10-19 | 2018-12-21 | 64981 |
| APO-RISEDRONATE | 150MG | TABLET | Resolved | 2017-10-23 | 2017-11-15 | 26643 |
| APO-RISPERIDONE | 0.50MG | TABLET | Resolved | 2017-12-14 | 2018-05-14 | 32827 |
| APO-RISPERIDONE | 1MG | SOLUTION | Resolved | 2017-12-14 | 2018-02-14 | 32834 |
| APO-RISPERIDONE | 1.0MG | TABLET | Resolved | 2017-06-28 | 2017-12-01 | 14216 |
| APO-RISPERIDONE | 2.0MG | TABLET | Resolved | 2017-06-28 | 2017-11-30 | 14219 |
| APO-RISPERIDONE | 0.50MG | TABLET | Resolved | 2017-07-26 | 2017-11-29 | 17319 |
Discontinuation reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-BISACODYL | 5MG | TABLET (DELAYED-RELEASE) | Discontinued | 2018-09-07 | 2018-09-15 | 60288 |
| APO-BOSENTAN | 62.5MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71339 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71342 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2018-09-07 | 2018-10-31 | 60291 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2020-11-16 | 2020-11-16 | 128438 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | To be discontinued | 2018-09-07 | 2018-09-07 | 60294 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2018-09-07 | 2018-12-28 | 60301 |
| APO-BROMAZEPAM | 1.5MG | TABLET | To be discontinued | 2018-09-07 | 2018-09-07 | 60304 |
| APO-BROMAZEPAM | 3MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60307 |
| APO-BROMAZEPAM | 6MG | TABLET | Discontinued | 2018-09-07 | 2018-10-19 | 60310 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60313 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60316 |
| APO-CANDESARTAN | 32MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60328 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60325 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60322 |
| APO-CANDESARTAN | 4MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60319 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60335 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60331 |
| APO-CANDESARTAN/HCTZ | 25MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-05-03 | 41011 |
| APO-CANDESARTAN/HCTZ | 12.5MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41020 |